Real-World Outcomes of Esketamine and Ketamine for TRD

Study Overview: Real-World Efficacy of Esketamine and Ketamine

A recent study published in OpenAlex explores the real-world outcomes of intranasal esketamine and intravenous (IV) ketamine for individuals with treatment-resistant depression (TRD) in a community clinic setting. The study, conducted from January to December 2025, involved 63 adults aged 18 to 65 who had not previously been exposed to these treatments. The primary measure was the change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline to the end of the induction phase.

The results indicate robust antidepressant effects for both treatments, with esketamine and ketamine showing significant reductions in PHQ-9 scores. However, the study's modest sample size and differences in treatment protocols limit the ability to draw definitive conclusions about the comparative efficacy of these therapies.

Mechanism and Context: Understanding NMDA Receptor Antagonists

Both intranasal esketamine and IV ketamine function as NMDA receptor antagonists, a class of drugs that modulate glutamatergic neurotransmission, which is believed to play a role in depression. Controlled trials have previously demonstrated their efficacy, but real-world data is crucial for understanding how these treatments perform outside of clinical trial settings.

This study provides valuable insights into the practical application of these therapies in community clinics, where factors such as insurance coverage and treatment logistics significantly impact clinical decisions. The study's findings align with controlled trial results, suggesting that these treatments can be effective for TRD in less controlled environments.

Policy and Research Implications: Practical Considerations

The findings of this study have important implications for clinicians and policymakers. The high response and remission rates observed in the study suggest that both treatments can be viable options for TRD, but practical considerations such as cost and insurance coverage may influence treatment choice. The study highlights the need for policies that support access to these therapies, particularly in community settings where resources may be limited.

Furthermore, the study underscores the importance of continued research into the long-term efficacy and safety of esketamine and ketamine, as well as the need for standardized protocols to facilitate comparisons across studies.

Risks and Unknowns: Limitations and Future Directions

While the study provides encouraging evidence of the efficacy of esketamine and ketamine, several limitations must be acknowledged. The small sample size and protocol differences between the treatment groups limit the study's power to detect between-group differences, increasing the risk of type II error. Additionally, the absence of serious adverse events in this study does not rule out the possibility of such events occurring in larger populations.

Future research should focus on larger, more diverse populations and explore the long-term effects of these treatments. Longitudinal follow-up studies are planned to assess the durability of treatment effects, which will be crucial for understanding the full potential of esketamine and ketamine in treating TRD.

Looking Ahead: The Future of TRD Treatment

The study's findings contribute to a growing body of evidence supporting the use of esketamine and ketamine for TRD. As more data becomes available, it will be essential to refine treatment protocols and address practical barriers to access. Clinicians and policymakers must work together to ensure that patients with TRD have access to effective treatments, considering both clinical efficacy and practical feasibility.

Ultimately, this study highlights the potential of esketamine and ketamine to transform the treatment landscape for TRD, offering hope to patients who have not responded to traditional antidepressants.